Rett Syndrome: A Rare Neurodevelopmental Disorder

Rett syndrome is a rare X-linked dominant neurodevelopmental disorder primarily affecting females (1:10,000–15,000 live female births).

Genetics

  • MECP2 mutations (>95%): Methyl-CpG-binding protein 2, transcriptional regulator. >500 pathogenic variants identified.
  • X-linked dominant, lethal in males: Most affected males die prenatally or in infancy. Surviving males: Klinefelter (XXY), somatic mosaicism, or mild MECP2 variants.
  • Atypical variants: CDKL5 (early-onset seizure variant), FOXG1 (congenital variant).

Clinical Course

  1. Stage I (6–18 mo): Developmental stagnation, reduced eye contact, hypotonia.
  2. Stage II (1–4 yr): Rapid regression: loss of speech, purposeful hand use; onset of stereotypic hand movements (wringing, washing, clapping).
  3. Stage III (2–10 yr): Plateau/pseudo-stationary: seizures, breathing abnormalities (hyperventilation, breath-holding), scoliosis, growth failure.
  4. Stage IV (>10 yr): Late motor deterioration: rigidity, loss of ambulation, scoliosis progression.

Diagnostic Criteria (2010 Consensus)

Required: Regression + recovery/stabilization + hand stereotypes + gait abnormalities. Supportive: breathing abnormalities, EEG abnormalities, scoliosis, growth retardation, cold hands/feet.

Management

  • Multidisciplinary: neurology, pulmonology, orthopedics, GI/nutrition, PT/OT/ST.
  • Seizure control (often refractory)
  • Scoliosis monitoring/bracing/surgery
  • Gastrostomy for nutrition
  • Communication aids (eye-gaze, AAC)
  • Trofinetide (Daybue) FDA-approved 2023: first disease-modifying treatment (improves behavioral scores).

Rare Disease Impact

Meets US definition (<200,000 affected). Challenges: diagnostic delay, fragmented care, limited treatments, family burden. Advocacy (IRSF, Rettsyndrome.org) drives research, newborn screening pilots, and clinical trials (gene therapy, MECP2 reactivation).

Genetic Disorders - Related Articles